Quarterly Revenue: Increased 75.4% year-over-year to $255.7 million. Genomics Revenue: $193.8 million, representing 89% year-over-year growth. Oncology Testing Growth: 31% year-over-year with approxim ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

Please go ahead. Thank you. Good afternoon and welcome to Tempus' first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

CHICAGO, May 05, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based health ...

Tempus AI Inc. TEM, a key holding in Cathie Wood's Ark Invest portfolio, reassured investors Tuesday that its major pharmaceutical contracts remain strong despite challenges in biotech funding and ...

Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today. Analysts expect revenue of $248.1 ...

Tempus AI (NASDAQ: TEM), a healthcare technology company, posted impressive Q1 results with revenue reaching $255.7 million, up 75.4% year-over-year. Adjusted EBITDA improved significantly to $-16 ...

Please go ahead. Thank you. Good afternoon. And welcome to Tempus’ first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Tuesday reported a loss of $68 million in its first quarter. On a per-share basis, the Chicago-based company said it had a loss of 40 cents.

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million ...